This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Frontiers in Cardiovascular Medicine
FEBRUARY 4, 2025
The exact role of subcutaneous adipose tissue in the interplay between type 2 diabetes (T2D) and coronary artery disease (CAD) is yet to be determined. The main molecular pathways involved were CXCR, NOTCH, STAT, NFKB1 and FGFR pathways, which have a well-documented role in diabetes and CAD.
Cardiovascular Diabetology
MAY 2, 2024
Insulin resistance and chronic kidney disease are both associated with increased coronary artery disease risk. Many formulae estimating glucose disposal rate in type 1 diabetes infer insulin sensitivity from c.
Cardiovascular Diabetology
AUGUST 6, 2024
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry.
Cardiovascular Diabetology
APRIL 4, 2024
Diabetes is a predominant driver of coronary artery disease worldwide. This study aims to unravel the distinct characteristics of oral and gut microbiota in diabetic coronary heart disease (DCHD). Simultaneous.
116 
Cardiovascular Diabetology
NOVEMBER 25, 2024
Type 1 diabetes increases the risk of coronary artery disease (CAD). High-throughput metabolomics may be utilized to identify metabolites associated with disease, thus, providing insight into disease pathophys.
HCPLive
OCTOBER 17, 2024
This analysis was conducted to evaluate whether genetic risk of hidradenitis suppurativa was linked to greater risk of future cardiometabolic disease.
Cardiology Update
MARCH 25, 2024
Left main coronary artery disease (CAD) and diabetes pose significant challenges in cardiovascular care, often leading to adverse outcomes. Preliminary evidence from trials focusing on patients with multivessel disease has hinted at diabetes as a potential modifier of treatment outcomes.
122 
Cardiovascular Diabetology
MARCH 7, 2025
Coronary artery disease (CAD) and diabetes mellitus (DM) can induce changes in myocardial structure and function, thereby increasing the risk of heart failure (HF). We aimed to identify the alterations in echo.
Cardiovascular Diabetology
OCTOBER 27, 2024
Diabetes mellitus (DM) is associated with premature atherosclerotic disease, coronary artery disease (CAD) and chronic heart failure (HF), leading to increased morbidity and mortality. Sodium-Glucose Co-transp.
Cardiovascular Diabetology
NOVEMBER 18, 2024
Individuals with type 1 diabetes are at increased risk of accelerated atherosclerosis, causing coronary artery disease (CAD). The underlying mechanisms remain unclear, but new theories proposed are damage of g.
Cardiovascular Diabetology
AUGUST 6, 2024
The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-intensity statin therapy for coronary artery disease (CAD) remains to be clarified. This st.
Frontiers in Cardiovascular Medicine
MARCH 14, 2025
PP criteria were: 50 years with diabetes mellitus, 1 additional CV risk factor, and triglycerides 150499mg/dl. In the SP cohort, coronary artery disease was the most common pre-existing CV disease (85.8%) and many had diabetes (63.1%). In the PP and SP cohorts, mean (SD) ages were 62.7 (8.0)
Cardiovascular Diabetology
FEBRUARY 23, 2024
Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Disease Risk in Diabetes (ACCORD) participants with the haptoglobin (Hp) 2-2 phenotype only.
Dr. Paddy Barrett
APRIL 26, 2024
Coronary artery disease is caused by the retention of a cholesterol particle in the artery wall. On the far end of that line is type two diabetes. On the far end of that line is type two diabetes. We also know that WHEN you get type 2 diabetes makes a huge difference. Let me be 100% clear, however.
104 
Cardiovascular Diabetology
MARCH 10, 2024
Stress hyperglycemia ratio (SHR) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are independently associated with increased mortality risk in diabetic patients with coronary artery disease (CAD).
American College of Cardiology
APRIL 26, 2024
Since limb events are major drivers of morbidity in diabetic patients with peripheral (PAD) and coronary artery disease (CAD), does the addition of ticagrelor to background therapy of aspirin improve limb events?
62 
Frontiers in Cardiovascular Medicine
FEBRUARY 7, 2024
Background In this study, we aim to investigate the relationship between the attenuation of peri-coronary adipose tissue (PCAT) in patients with suspected coronary artery disease (CAD) and the assessment of coronary vascular functions using coronary flow reserve (CFR).
American Heart News - Heart News
JANUARY 16, 2024
Research shows that chronic gum inflammation may be associated with other chronic diseases including coronary artery disease and diabetes.[1] DALLAS, JANUARY 16, 2024 — A patient’s oral health can be an indicator of overall health and well-being.
Cardiovascular Diabetology
FEBRUARY 6, 2025
Epicardial and pericardial adipose tissues are two distinct types of visceral fat in close adherence to the heart and were found to be increased among diabetics.
Frontiers in Cardiovascular Medicine
FEBRUARY 20, 2024
We investigated whether treatment with LDE-paclitaxel changes plaque progression by coronary CT angiography and is safe in patients with chronic coronary artery disease. Analysis of inflammatory biomarkers and coronary CTA was also performed at baseline and 4 weeks after treatment.
Cardiovascular Diabetology
MARCH 27, 2025
Pericoronary adipose tissue attenuation (PCATa), derived from coronary computed tomography angiography (CCTA), is a novel marker of inflammation in the coronary arteries. Patients with type 2 diabetes mellitus.
Cardiovascular Diabetology
AUGUST 27, 2024
Objective We aimed to summarize the association between gestational diabetes mellitus (GDM) and its intergenerational cardiovascular diseases (CVDs) impacts in both mothers and offspring post-delivery in existing literature.
Journal of Cardiovascular Pharmacology
MAY 20, 2024
Our objective was to assess whether metformin could mitigate statin-induced adverse effects on PCSK9, thereby improving lipid profiles in patients with coronary artery disease (CAD) but without diabetes. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Dr. Paddy Barrett
APRIL 5, 2024
A common feedback I get is that people with existing coronary artery disease feel like it doesn’t apply to them. Arguably, applying the principles of prevention offers more bang for buck in the short term for people WITH coronary artery disease than those without coronary artery disease.
117 
Cardiovascular Diabetology
FEBRUARY 2, 2024
The outcomes of percutaneous coronary intervention (PCI) in diabetic patients are still suboptimal, and it is unclear if diabetic patients might derive a benefit from the use of drug-coated balloons.
Cardiovascular Diabetology
JANUARY 5, 2024
The role of triglyceride-glucose (TyG) index, an insulin resistance indicator, in glycemic management for diabetic patients with coronary artery disease (CAD) was still unknown. Therefore, we aimed to explore.
MIBHS
MARCH 31, 2025
Seeking emergency medical attention can restore blood flow and prevent further damage. Without immediate intervention, sudden cardiac death can occur within minutes. Preventing Heart Attacks and Cardiac Arrest Maintaining a healthy lifestyle can reduce the risk of both heart attack and cardiac arrest.
Circulation
MARCH 11, 2024
Patients were categorized by diabetes status. Kaplan-Meier event rates, Cox model hazard ratios, and interactions were assessed.RESULTS:Among 4393 patients, 1104 (25.1%) had diabetes. PintHR=0.87) diabetes. Patients were considered suitable for either approach. and 9.9%) compared with those without (2.1%
Circulation
NOVEMBER 11, 2024
Introduction:Patients with Type 2 diabetes mellitus (T2DM) have an increased risk for coronary artery disease (CAD) compared to patients without T2DM. Circulation, Volume 150, Issue Suppl_1 , Page A4136459-A4136459, November 12, 2024.
Circulation
NOVEMBER 11, 2024
Background:Clinical trials have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) reduce cardiovascular (CV) risk in patients (pts) with type 2 diabetes (T2D) with or at high risk for CV disease.
Frontiers in Cardiovascular Medicine
JULY 21, 2024
BackgroundThis Mendelian randomization (MR) study aimed to explore the causal relationship between the genetic predisposition to type 2 diabetes mellitus (T2DM) and aortic dissection (AD), and to assess associations with genetically predicted glycemic traits. The findings remained stable across various MR models and sensitivity analyses.
Frontiers in Cardiovascular Medicine
DECEMBER 9, 2024
BackgroundLow-Density Lipoprotein Cholesterol (LDL-C) is the primary lipid therapy target for coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI). High RLP-C levels increased the risk of revascularization.
98 
DAIC
MARCH 1, 2024
Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue. Treating ISR has been challenging in the U.S.
105 
Circulation
NOVEMBER 11, 2024
The nomogram consists of age, smoking, hypertension, diabetes mellitus (DM), hyperuricemia, and FFR≤0.8 The prediction efficiency of nomogram was evaluated by multiple methods, including C-index, area under the curve (AUC), calibration curves and decision-curve analysis (DCA).Results:During Results:During a median follow-up of 6.2
Cardiovascular Diabetology
OCTOBER 8, 2024
had a higher risk of coronary artery disease (CAD) compared to those with HbA1c 7.0–7.9%. In the ACCORD study, participants with the haptoglobin (Hp) 2–2 phenotype and glycated hemoglobin (HbA1c) ≥ 8.0% However,
Dr. Paddy Barrett
OCTOBER 4, 2024
But the goal in this instance is to die after a long and healthy life ‘ with ’ coronary artery disease rather than ‘ from ’ coronary artery disease. However, the chances of dying from heart disease are directly proportional to the amount of plaque in your coronary arteries.
102 
DAIC
APRIL 9, 2024
The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Patients had had Type 2 diabetes for an average of 14 years. Decline in exercise ability is a hallmark of progression to overt heart failure.
DAIC
JULY 23, 2024
Haechan Cho, MD received Best Abstract first runner-up after presenting his abstract, “Coronary Computed Tomography Angiography Versus Functional Testing In Patients With Diabetes And Suspected Coronary Artery Disease: Real-world Evidence From The Nationwide Cohort.”
105 
Dr. Paddy Barrett
MAY 20, 2024
Every day we learn something new about the complexity of coronary artery disease. But we have known for decades that getting these core factors right substantially reduces your risk of heart disease. Avoiding diabetes. This is a huge difference. Being physically active. Not smoking. Having good nutrition.
Dr. Paddy Barrett
DECEMBER 13, 2024
Excess visceral fat results in a higher risk of insulin resistance, which is the precursor state to diabetes. In the setting of insulin resistance, a higher ApoB concentration increases the risk of cardiovascular disease dramatically. Relationship of BMI and Risk Of Diabetes. You put their diabetes into remission.
Dr. Paddy Barrett
JUNE 21, 2024
The same is true of uncontrolled diabetes or high blood pressure. What I am trying to get across is that it is very common for a parent to have had heart disease, but that does not mean it has a genetic origin. Most of the time, coronary artery disease will be the cause. But not always. What To Look For Ok.
DAIC
MARCH 6, 2024
milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its Coronary Artery Disease ( CAD ) Staging System.
105 
Circulation
NOVEMBER 11, 2024
p=0.009) but not in Group-M or in Group-H.Cox proportional hazard model analysis including clinical variables showed that severe endothelial dysfunction was a significant predictor for future diabetic evolution (hazard ratio=2.69, p=0.011) and all-causal death (hazard ratio=5.87, p=0.009).Conclusions:This
40 
MIBHS
FEBRUARY 28, 2025
A family history of heart disease often indicates that genetic factors might be at play. Common Heart Diseases with Genetic Links Coronary Artery Disease (CAD): CAD occurs when the arteries supplying blood to the heart become narrowed or blocked.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content